Related Experiment Video
Updated: Feb 3, 2026

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
Published on: July 29, 2012
Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the
Insights
Chagas disease, caused by Trypanosoma cruzi, is increasingly prevalent in non-endemic areas like the US. Healthcare providers need updated guidance on diagnosing and managing this parasitic infection, especially its cardiac complications.
Area of Science:
- Cardiology
- Infectious Diseases
- Parasitology
Background:
- Chagas disease, caused by Trypanosoma cruzi, is a significant cause of cardiovascular morbidity and mortality.
- Once considered tropical, it now affects over 300,000 in the US and is rising in non-endemic regions.
- Urgent need for healthcare systems outside Latin America to recognize, diagnose, and treat Chagas disease.
Purpose of the Study:
- Increase global awareness of Chagas disease among healthcare providers.
- Provide updated information on diagnosis, screening, and treatment of Trypanosoma cruzi infection.
- Focus on cardiovascular manifestations and management of Chagas cardiomyopathy.
Main Methods:
- Commissioned statement by the American Heart Association and Inter-American Society of Cardiology.
- Summarizes current knowledge and practices in Chagas disease diagnosis and management.
- Includes quick reference tables for suspected or confirmed cases.
Main Results:
- Chagas disease presents significant cardiovascular risks including heart failure, stroke, and arrhythmia.
- Growing prevalence in the US necessitates improved diagnostic and treatment protocols.
- Updated guidance is crucial for managing Chagas cardiomyopathy in diverse settings.
Conclusions:
- This statement aims to enhance recognition of Chagas cardiomyopathy in low-prevalence areas.
- Improve the care and management of patients with Chagas heart disease globally.
- Equip healthcare providers with essential knowledge for Chagas disease patient care.
Background:
Chagas disease, resulting from the protozoan Trypanosoma cruzi, is an important cause of heart failure, stroke, arrhythmia, and sudden death. Traditionally regarded as a tropical disease found only in Central America and South America, Chagas disease now affects at least 300 000 residents of the United States and is growing in prevalence in other traditionally nonendemic areas. Healthcare providers and health systems outside of Latin America need to be equipped to recognize, diagnose, and treat Chagas disease and to prevent further disease transmission.
Methods And Results:
The American Heart Association and the Inter-American Society of Cardiology commissioned this statement to increase global awareness among providers who may encounter patients with Chagas disease outside of traditionally endemic environments. In this document, we summarize the most updated information on diagnosis, screening, and treatment of T cruzi infection, focusing primarily on its cardiovascular aspects. This document also provides quick reference tables, highlighting salient considerations for a patient with suspected or confirmed Chagas disease.
Conclusions:
This statement provides a broad summary of current knowledge and practice in the diagnosis and management of Chagas cardiomyopathy. It is our intent that this document will serve to increase the recognition of Chagas cardiomyopathy in low-prevalence areas and to improve care for patients with Chagas heart disease around the world.
Related Concept Videos
Cardiomyopathy VI: Nursing Management
Scientific Laws and Theories
The Scientific Method
The Scientific Method
Generally, predictions are tested using carefully-designed experiments. Based on the outcome of these...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management

